Q-omics provides the consensus-scored PRSS57 profile across patient tissues and cancer cell-line models. PRSS57 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PRSS57 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PRSS57 RNA expression shows 9,640 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where PRSS57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS57 survival associations across molecular data types. PRSS57 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS57 RNA expression–survival associations across cancer types. High PRSS57 expression shows unfavorable associations in ESCA and UCS, but favorable associations in HNSC, UVM, STAD and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for PRSS57 RNA expression.
This table summarizes PRSS57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRSS57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS57 shows lower tumor expression in KICH, LUAD and UCEC and higher tumor expression in THCA, KIRC and KIRP. The KICH box plot shows higher PRSS57 RNA expression in normal versus tumor tissue (log2 FC = −0.288, t-test p < 0.001).
This table shows molecular features associated with PRSS57 in patient tissues and cancer cell lines. In patient samples, PRSS57 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
